Options Brief: Medivation (MDVN)

Shares of Medivation MDVN are higher on the session by 3.75%, trading at $11.63. Overall put volume is now running at 25.93x the daily average, with 8% of all puts traded being purchases on the offer. 1,115 contracts have traded on the session so far. Medivation, Inc. is a biopharmaceutical company. The company focuses on the development of small molecule drugs to treat serious diseases. The Company's product candidates in clinical development are dimebon, which is in Phase III development for the treatment of Alzheimer's disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer.